Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s ...

Zealand Pharma is working on the next-gen weight-loss treatment. Its Petrelintide showed promising results in a Phase 1b ...

After third-party manufacturing issues led to a December rejection of Zealand Pharma’s pediatric congenital hyperinsulinism (CHI) candidate, the Danish pharma’s latest snub seems to come down to ti | ...

Denmark stocks were higher after the close on Friday, as gains in the Consumer Goods, Healthcare and Financials sectors led ...

Amid the stock market frenzy surrounding weight-loss medicines, one Belgian biotech company is rewarding investors by ...

Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and ...

Within Novo Nordisk's comprehensive business update ... and Boehringer Ingelheim/Zealand Pharma start to eye a market that has been estimated to be worth $100 billion within a decade.

Sensex, Nifty updates on 7 October 2024 - Equity benchmark indices, Sensex and Nifty, extended their losing streak to a sixth ...

No. 48 / 2024Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinismU.S. Food and ...

Zealand Pharma said it has received a complete response letter from the Food and Drug Administration related to its new drug application for dasiglucagon for the prevention and treatment of ...